Related Experiment Videos

Bioavailability of the antiemetic metopimazine given as a microenema

J Herrstedt1, M Jørgensen, H R Angelo

  • 1Department of Oncology, Herlev Hospital, University of Copenhagen, Denmark.

Insights

This study compared metopimazine (MPZ) absorption via microenema, oral, and IV routes in healthy volunteers. Rectal administration via microenema offered partial avoidance of first-pass metabolism, suggesting reliable drug delivery.

Area of Science:

  • Pharmacology
  • Gastroenterology
  • Drug Metabolism

Background:

  • Metopimazine (MPZ) is an antiemetic drug.
  • Understanding its absorption is crucial for effective therapeutic use.
  • Rectal drug administration can bypass hepatic first-pass metabolism.

Purpose of the Study:

  • To investigate the absorption and bioavailability of metopimazine (MPZ).
  • To compare MPZ absorption following oral, microenema, and intravenous administration.
  • To assess the impact of rectal administration on hepatic first-pass metabolism.

Main Methods:

  • Six healthy volunteers received single doses of MPZ.
  • Administration routes included 40 mg microenema, 40 mg orally, and 10 mg IV infusion.
  • Serum concentrations of MPZ and its acid metabolite were measured.

Main Results:

  • Oral MPZ bioavailability was 22.3%; microenema bioavailability was 19.5%.
  • Microenema administration showed partial avoidance of hepatic first-pass metabolism.
  • Rectal administration via microenema appears reliable.

Conclusions:

  • Metopimazine exhibits moderate oral bioavailability.
  • Microenema administration provides a reliable rectal route for MPZ, bypassing some hepatic metabolism.
  • This suggests potential advantages for rectal delivery in specific clinical scenarios.

Related Concept Videos